757 Histologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY

Peyrin‐Biroulet, Laurent; Colombel, Jean‐Frédéric; V. Loftus, Edward; Danese, Silvio; Abhyankar, Brihad; Chen, Jingjing; Rogers, Raquel; A. Lirio, Richard; D. Bornstein, Jeffrey; E. Sands, Bruce; Schreiber, Stefan

doi:10.14309/01.ajg.0000592564.74380.03

Public

757 Histologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY

Published in The American Journal of Gastroenterology • Oct 1, 2019

Authors:

Laurent Peyrin‐Biroulet

Jean‐Frédéric Colombel

Edward V. Loftus

Abstract

INTRODUCTION: Histologic remission is associated with superior long-term clinical outcomes in ulcerative colitis (UC). VARSITY, the first head-to-head comparison of biologic agents in UC (NCT02497469; EudraCT 2015-000939-33), showed superior clinical remission and endoscopic improvement at Week 52 w...

Subject

Vedolizumab

Medicine

Ulcerative colitis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!